한글목차

에토리콕시브 세계 시장은 2024년에 1억 1,078만 달러로 평가되었고, 2030년에는 2억 7,144만 달러에 달할 것으로 예상되며, 예측 기간 동안 12.06%의 복합 연간 성장률(CAGR)을 보일 것으로 예측됩니다.

이 시장은 효과적인 항염증 치료에 대한 수요 증가와 골관절염, 류마티스 관절염, 만성 통증 질환 등의 유병률 증가로 인해 안정적인 성장세를 보이고 있습니다.

선택적 사이클로옥시게나제-2(COX-2) 억제제인 에토리콕시브는 이러한 질환에 수반되는 통증 및 염증 관리에 널리 사용되고 있습니다. 비스테로이드성 항염증제(NSAID)로서 기존의 NSAID와 관련된 위장관계 부작용 가능성을 감소시키는 표적 작용기전으로 인해 선호되고 있으며, COX-1이 아닌 COX-2를 선택적으로 억제함으로써 통증 및 염증 관리에 보다 정확한 접근법을 제공합니다. 접근법을 제공합니다. 이러한 약리학적 장점으로 인해 특히 고령자나 소화기 합병증 병력이 있는 환자에서 장기적으로 사용하기에 적합합니다. 우수한 안전성 프로파일로 인해 의료 전문가와 환자 모두에서 지속적으로 채택되고 있습니다.

주요 시장 성장 촉진요인

세계 헬스케어 산업의 성장

주요 시장 이슈

공급망 취약성

주요 시장 동향

표적 통증 완화의 중요성

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 COVID-19가 세계의 에토리콕시브 시장에 미치는 영향

제5장 세계의 에토리콕시브 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 판매채널별(직접, 간접)
  • 용도별(골관절염, 류마티스 관절염, 강직성 척추염, 급성 통풍성 관절염, 기타)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 북미의 에토리콕시브 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 미국
  • 멕시코
  • 캐나다

제7장 유럽의 에토리콕시브 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 프랑스
  • 독일
  • 영국
  • 이탈리아
  • 스페인

제8장 아시아태평양의 에토리콕시브 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 중국
  • 인도
  • 한국
  • 일본
  • 호주

제9장 남미의 에토리콕시브 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 브라질
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 에토리콕시브 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 남아프리카공화국
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 인수합병(M&A)
• 제품 출시
• 최근 동향

제13장 세계의 에토리콕시브 시장 : SWOT 분석

제14장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제15장 경쟁 구도

• Orex Pharma
• Aurore Life Sciences
• Hetero
• Aoki Medicinal
• Guangdong Raffles Pharma Tech Co.,Ltd
• Sichuan Yujian Pharmaceutical Co., Ltd
• Gennex Laboratories Limited
• Cipla Limited
• MICRO LABS LIMITED
• Greenkem Organics Pvt Ltd

제16장 전략적 제안

제17장 리서치사에 대해 & 면책사항

영문목차

Global Etoricoxib Market was valued at USD 110.78 million in 2024 and is projected to reach USD 271.44 million by 2030, growing at a compound annual growth rate (CAGR) of 12.06% during the forecast period. This market is experiencing consistent growth, primarily driven by the rising demand for effective anti-inflammatory treatments and the increasing prevalence of conditions such as osteoarthritis, rheumatoid arthritis, and chronic pain disorders.

Etoricoxib, a selective cyclooxygenase-2 (COX-2) inhibitor, is widely used for the management of pain and inflammation associated with these medical conditions. As a nonsteroidal anti-inflammatory drug (NSAID), it is preferred due to its targeted mechanism of action, which reduces the likelihood of gastrointestinal side effects typically associated with conventional NSAIDs. By selectively inhibiting COX-2 rather than COX-1, etoricoxib offers a more precise approach to pain and inflammation management. This pharmacological advantage makes it particularly suitable for long-term use, especially among elderly patients or those with a history of gastrointestinal complications. Its favorable safety profile continues to drive adoption among both healthcare professionals and patients.

Key Market Drivers

Growth of the Global Healthcare Industry

The global expansion of the healthcare sector is a significant factor contributing to the increased demand for etoricoxib. As a selective COX-2 inhibitor, etoricoxib is widely recognized for its analgesic and anti-inflammatory properties. The healthcare industry, one of the fastest-growing economic sectors worldwide, accounts for more than 10% of GDP in many developed economies. For instance, healthcare spending in the United States rose by 2.7% in 2021, reaching USD 4.3 trillion, or approximately USD 12,914 per capita.

With ongoing improvements and expansion in healthcare systems-particularly across emerging markets-the demand for effective pain management solutions has surged. Etoricoxib's ability to treat chronic conditions such as osteoarthritis, rheumatoid arthritis, and acute pain positions it as a valuable addition to modern, patient-centered treatment plans.

Key Market Challenges

Supply Chain Vulnerabilities

The production of etoricoxib depends on the availability of pharmaceutical-grade raw materials and intermediate compounds. Disruptions in the supply chain-whether due to bottlenecks, regulatory restrictions, or volatility in raw material prices-can significantly delay manufacturing and impact product availability. For example, shortages or cost increases in essential inputs may lead to elevated production costs, reducing profit margins or resulting in higher prices for end-users.

Geopolitical factors such as trade disputes, tariffs, and regional instability further complicate global supply chains. Given that etoricoxib manufacturers typically depend on a network of international suppliers and contract manufacturers, any disruption-whether due to customs delays, export restrictions, or geopolitical conflict-poses a substantial risk. These challenges are particularly critical in the pharmaceutical industry, where timely access to medications is essential for patient care.

Key Market Trends

Emphasis on Targeted Pain Relief

A growing trend in the global etoricoxib market is the increasing emphasis on targeted pain management, especially in the context of chronic pain and inflammation. Etoricoxib, as a selective COX-2 inhibitor, is approved for short-term relief of moderate post-operative dental pain and for treating pain and inflammation associated with various forms of arthritis.

With the healthcare industry shifting toward precision medicine, there is a heightened focus on therapies that provide safer, more personalized, and more effective treatment outcomes. Etoricoxib is gaining traction due to its ability to precisely target pain and inflammatory pathways while minimizing the adverse effects typically linked to traditional NSAIDs.

Unlike non-selective NSAIDs that inhibit both COX-1 and COX-2 enzymes, etoricoxib's selective inhibition of COX-2 is associated with a lower risk of gastrointestinal and cardiovascular complications. This makes it an attractive option for long-term pain management, particularly in older adults and patients with preexisting health conditions.

Key Market Players

• Orex Pharma
• Aurore Life Sciences
• Hetero
• Aoki Medicinal
• Guangdong Raffles Pharma Tech Co.,Ltd
• Sichuan Yujian Pharmaceutical Co., Ltd
• Gennex Laboratories Limited
• Cipla Limited
• MICRO LABS LIMITED
• Greenkem Organics Pvt Ltd

Report Scope

In this report, the Global Etoricoxib Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Etoricoxib Market, By Sales Channel:

• Direct
• Indirect

Etoricoxib Market, By End Use:

• Osteoarthritis
• Rheumatoid Arthritis
• Ankylosing Spondylitis
• Acute Gouty Arthritis
• Others

Etoricoxib Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Etoricoxib Market.

Available Customizations:

Global Etoricoxib Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global Etoricoxib Market

5. Global Etoricoxib Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Sales Channel (Direct, Indirect)
  • 5.2.2. By End Use (Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, Acute Gouty Arthritis, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America Etoricoxib Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Sales Channel
  • 6.2.2. By End Use
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Etoricoxib Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Sales Channel
      • 6.3.1.2.2. By End Use
  • 6.3.2. Mexico Etoricoxib Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Sales Channel
      • 6.3.2.2.2. By End Use
  • 6.3.3. Canada Etoricoxib Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Sales Channel
      • 6.3.3.2.2. By End Use

7. Europe Etoricoxib Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Sales Channel
  • 7.2.2. By End Use
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Etoricoxib Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Sales Channel
      • 7.3.1.2.2. By End Use
  • 7.3.2. Germany Etoricoxib Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Sales Channel
      • 7.3.2.2.2. By End Use
  • 7.3.3. United Kingdom Etoricoxib Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Sales Channel
      • 7.3.3.2.2. By End Use
  • 7.3.4. Italy Etoricoxib Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Sales Channel
      • 7.3.4.2.2. By End Use
  • 7.3.5. Spain Etoricoxib Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Sales Channel
      • 7.3.5.2.2. By End Use

8. Asia Pacific Etoricoxib Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Sales Channel
  • 8.2.2. By End Use
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Etoricoxib Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Sales Channel
      • 8.3.1.2.2. By End Use
  • 8.3.2. India Etoricoxib Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Sales Channel
      • 8.3.2.2.2. By End Use
  • 8.3.3. South Korea Etoricoxib Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Sales Channel
      • 8.3.3.2.2. By End Use
  • 8.3.4. Japan Etoricoxib Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Sales Channel
      • 8.3.4.2.2. By End Use
  • 8.3.5. Australia Etoricoxib Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Sales Channel
      • 8.3.5.2.2. By End Use

9. South America Etoricoxib Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Sales Channel
  • 9.2.2. By End Use
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Etoricoxib Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Sales Channel
      • 9.3.1.2.2. By End Use
  • 9.3.2. Argentina Etoricoxib Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Sales Channel
      • 9.3.2.2.2. By End Use
  • 9.3.3. Colombia Etoricoxib Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Sales Channel
      • 9.3.3.2.2. By End Use

10. Middle East and Africa Etoricoxib Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Sales Channel
  • 10.2.2. By End Use
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Etoricoxib Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Sales Channel
      • 10.3.1.2.2. By End Use
  • 10.3.2. Saudi Arabia Etoricoxib Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Sales Channel
      • 10.3.2.2.2. By End Use
  • 10.3.3. UAE Etoricoxib Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Sales Channel
      • 10.3.3.2.2. By End Use

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Etoricoxib Market: SWOT Analysis

14. Porters Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Orex Pharma
  • 15.1.1. Business Overview
  • 15.1.2. Company Snapshot
  • 15.1.3. Products & Services
  • 15.1.4. Financials (As Reported)
  • 15.1.5. Recent Developments
  • 15.1.6. Key Personnel Details
  • 15.1.7. SWOT Analysis
• 15.2. Aurore Life Sciences
• 15.3. Hetero
• 15.4. Aoki Medicinal
• 15.5. Guangdong Raffles Pharma Tech Co.,Ltd
• 15.6. Sichuan Yujian Pharmaceutical Co., Ltd
• 15.7. Gennex Laboratories Limited
• 15.8. Cipla Limited
• 15.9. MICRO LABS LIMITED
• 15.10. Greenkem Organics Pvt Ltd

16. Strategic Recommendations

17. About Us & Disclaimer